Variability in functional p53 reactivation by PRIMA-1 Met/APR-246 in Ewing sarcoma

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2696-2704

  Aryee, D N T ^a,b   Niedan, S ^a   Ban, J ^a   Schwentner, R ^a   Muehlbacher, K ^a   Kauer, M ^a   Kofler, R ^c   Kovar, H ^a,b  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (HYDROXYMETHYL) 2 (METHOXYMETHYL) 1 AZABICYCLO[2.2.2.]OCTAN 3 ONE; ANTINEOPLASTIC AGENT; APR 246; AZABICYCLO DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOL6 GENE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; EWING SARCOMA; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETIC TRANSFECTION; MST4 GENE; MUTANT; NUCLEOTIDE SEQUENCE; PCDH7 GENE; PENK GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; TRANSCRIPTOMICS; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICROARRAY ANALYSIS; MUTATION; QUINUCLIDINES; RNA, SMALL INTERFERING; SARCOMA, EWING; TRANSCRIPTOME; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887846605     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.635     Document Type: Article

References (42)

1. Aryee DN, Niedan S, Kauer M, Schwentner R, Bennani-Baiti IM, Ban J, Muehlbacher K, Kreppel M, Walker RL, Meltzer P, Poremba C, Kofler R, Kovar H (2010) Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro. Cancer Res 70(10): 4015-4023.
2. Ban J, Bennani-Baiti IM, Kauer M, Schaefer KL, Poremba C, Jug G, Schwentner R, Smrzka O, Muehlbacher K, Aryee DN, Kovar H (2008) EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma. Cancer Res 68(17): 7100-7109.
3. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104(3): 263-269.
4. Burns TF, El-Deiry WS (1999) The p53 pathway and apoptosis. J Cell Physiol 181(2): 231-239.
5. Bykov VJ, Issaeva N, Selivanova G, Wiman KG (2002a) Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23(12): 2011-2018.
6. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002b) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3): 282-288.
7. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6(10): 1791-1797.
8. Chipuk JE, Maurer U, Green DR, Schuler M (2003) Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4(5): 371-381.
9. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-Mindan FJ, Healey JH, Ladanyi M (2000) Prognostic impact of P53 status in Ewing sarcoma. Cancer 89(4): 783-792.
10. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10): R80.
11. Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458(7242): 1127-1130.
12. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P, Ladanyi M (2005) Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 23(3): 548-558.
13. Huovinen M, Loikkanen J, Myllynen P, Vahakangas KH (2011) Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis. Toxicol In Vitro 25(5): 1007-1017.
14. Kovar H, Auinger A, Jug G, Aryee D, Zoubek A, Salzer-Kuntschik M, Gadner H (1993) Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 8(10): 2683-2690.
15. Kovar H, Ban J, Pospisilova S (2003a) Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol 13(4): 275-281.
16. Kovar H, Pospisilova S, Jug G, Printz D, Gadner H (2003b) Response of Ewing tumor cells to forced and activated p53 expression. Oncogene 22(21): 3193-3204.
17. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15(5): 376-388.
18. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ (2010) Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 29(9): 1329-1338.
19. Li Y, Li X, Fan G, Fukushi J, Matsumoto Y, Iwamoto Y, Zhu Y (2012) Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Cancer Lett 320(1): 14-22.
20. Liang Y, Besch-Williford C, Hyder SM (2009) PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol 35(5): 1015-1023.
21. Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA (2005) Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res 3(1): 21-31.
22. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S, Serra M, Calabuig-Farinas S, Picci P, Llombart-Bosch A (2011) Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 128(5): 1139-1150.
23. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21(3): 485-495.
24. McTavish N, Copeland LA, Saville MK, Perkins ND, Spruce BA (2007) Proenkephalin assists stress-activated apoptosis through transcriptional repression of NF-kappaB-and p53-regulated gene targets. Cell Death Differ 14(9): 1700-1710.
25. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A (2012) Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 109(8): 2730-2735.
26. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80(2): 293-299.
27. Nakano K, Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7(3): 683-694.
28. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM (2011) Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 17(3): 494-504.
29. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357(25): 2552-2561.
30. Robles AI, Bemmels NA, Foraker AB, Harris CC (2001) APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61(18): 6660-6664.
31. Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, Koch WM (2011) p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 47(1): 8-15.
32. Rokaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT (2010) PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 29(49): 6442-6451.
33. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3(6): 1101-1108.
34. Selivanova G (2004) p53: fighting cancer. Curr Cancer Drug Targets 4(5): 385-402.
35. Selivanova G (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20(1): 46-56.
36. Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT, Bargou RC (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106(10): 3609-3617.
37. Sung V, Luo W, Qian D, Lee I, Jallal B, Gishizky M (2003) The Ste20 kinase MST4 plays a role in prostate cancer progression. Cancer Res 63(12): 3356-3363.
38. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 103(6): 1888-1893.
39. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659): 844-848.
40. Vousden KH, Lu X (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2(8): 594-604.
41. Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS (2011) PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 17(9): 2830-2841.
42. Zhang Z, DuBois RN (2001) Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 20(33): 4450-4456.